What would this technology cost compared to current chiral detectors?+
The project data does not specify a unit price. However, the objective notes that sensitivity improvements of 3-6 orders of magnitude depend on instrument complexity and price, suggesting a range of configurations from affordable to high-end. The total EU contribution was EUR 3,999,250 across 8 partners over 5 years, which funded R&D rather than production costs.
Can this scale to high-throughput industrial use?+
The technology was designed to couple with standard HPLC systems, which are already high-throughput workhorses in pharma and chemical labs. A portable standalone prototype was delivered by the JGU partner, demonstrating the system can work outside a laboratory setting. Scaling to production volumes would require engineering the prototype into a commercial instrument.
What is the IP situation — can I license this?+
The project was funded as a Research and Innovation Action (RIA) under Horizon 2020. IP generated typically belongs to the consortium partners, primarily the coordinator IDRYMA TECHNOLOGIAS KAI EREVNAS in Greece and JGU in Germany which built the portable prototype. Licensing discussions would need to go through these institutions.
Has this been tested with real-world samples?+
The project objective describes five concrete application domains including in-situ protein measurement, HPLC coupling, bodily fluid analysis, single-molecule detection, and atmospheric monitoring of terpene emissions from trees. The portable prototype deliverable specifically mentions field studies, indicating real-world testing was part of the plan.
How does this compare to existing commercial instruments?+
According to the project data, the Chiral Cavity Polarimetry (CCP) method improves chiral detection sensitivity by 3-6 orders of magnitude compared to commercial instruments. It achieves this through roughly 1,000 cavity passes that enhance the signal, suppression of birefringent backgrounds, and rapid signal reversals that eliminate the need to remove the sample for baseline measurement.
What regulatory approvals would be needed?+
Based on available project data, no regulatory submissions are mentioned. For pharmaceutical HPLC use, the detector would need validation under pharmacopoeia standards. For medical diagnostics of bodily fluids, CE-IVD marking or FDA clearance would be required depending on the market. These steps remain ahead.
What is the realistic timeline to a commercial product?+
The project ran from 2017 to 2021 and delivered a portable prototype. Moving from prototype to commercial instrument typically requires 2-4 years of engineering, certification, and manufacturing setup. Based on available project data, no commercial launch has been announced yet.
